Detalhe da pesquisa
1.
Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients.
World J Urol
; 35(4): 517-526, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26694187
2.
Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives.
Biochim Biophys Acta
; 1846(2): 630-7, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25450825
3.
Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma.
Biochim Biophys Acta
; 1845(2): 221-31, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24480319
4.
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.
Cancer Metastasis Rev
; 33(1): 321-31, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24337954
5.
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
J Urol
; 193(1): 41-7, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25046616
6.
High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer.
Ann Surg Oncol
; 22(4): 1377-84, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25234022
7.
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Ann Surg Oncol
; 22(6): 2094-100, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25472645
8.
Inside the 2015 ASCO Genitourinary Cancers Symposium.
Future Oncol
; 11(13): 1859-62, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26161923
9.
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor.
Int J Cancer
; 134(12): 2772-7, 2014 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24114790
10.
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Int J Cancer
; 135(4): 763-73, 2014 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24127298
11.
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
Future Oncol
; 10(10): 1741-50, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24641206
12.
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma.
Cancer Immunol Immunother
; 62(12): 1757-68, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24132754
13.
Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma.
J Neurooncol
; 113(3): 397-401, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23564276
14.
Level IV tumor thrombus in non-metastatic renal cell cancer? No, thanks. Level II is better. Lessons learned from a case report.
Urol Case Rep
; 37: 101660, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33868935
15.
Seminoma Retroperitoneal Relapse 23 Years After Surgery.
Oncol Ther
; 9(1): 239-245, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33606194
16.
Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma.
Anticancer Res
; 38(10): 5773-5782, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30275199
17.
Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges.
Cancer Treat Rev
; 48: 20-4, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27310708
18.
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus.
Clin Genitourin Cancer
; 14(5): 426-431, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27021585
19.
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Oncotarget
; 7(25): 37599-37607, 2016 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27175586
20.
Prostate cancer: from Gleason scoring to prognostic grade grouping.
Expert Rev Anticancer Ther
; 16(4): 433-40, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27008205